Infliximab ELISA (REMICADE)

Intended Use: This Infliximab ELISA is used as an analytical tool for quantitative laboratory screening of presence or absence of Infliximab in serum and plasma.

Assay Background: Infliximab is a monoclonal antibody which has high specificity for TNF ±, and does not neutralize TNF beta. Infliximab causes programmed cell death of TNF ±-expressing activated T lymphocytes, an important cell type mediating inflammation; hence it is generally assumed that resolution of activated T cells by Infliximab explains its efficacy in Crohn's disease.

Assay Principle: The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Infliximab are precoated onto microwells. Samples and standards are pipetted into microwells and human Infliximab present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated anti- Infliximab antibody is pipetted and incubated with samples. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Infliximab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.